eficur vet. stungulyf, dreifa 50 mg/ml
laboratorios hipra s.a.* - ceftiofurum hýdróklóríð - stungulyf, dreifa - 50 mg/ml
ceftriaxona normon innrennslisstofn, lausn 2000 mg
laboratorios normon, s.a. - ceftriaxonum dínatríum - innrennslisstofn, lausn - 2000 mg
ceftriaxona normon stungulyfs-/innrennslisstofn og leysir, lausn 1000 mg
laboratorios normon, s.a. - ceftriaxonum dínatríum - stungulyfs-/innrennslisstofn og leysir, lausn - 1000 mg
flucloxacillin wh stungulyfs-/innrennslisstofn, lausn 1000 mg
williams & halls ehf.* - flucloxacillinum natríum - stungulyfs-/innrennslisstofn, lausn - 1000 mg
piperacillin/tazobactam wh innrennslisstofn, lausn 4 g/0,5 g
williams & halls ehf. - piperacillinum natríum; tazobactamum natríum - innrennslisstofn, lausn - 4 g/0,5 g
poulvac flufend h5n3 rg
pfizer limited - raðbrigða óvirkt fuglainflúensuveiru - Ónæmisfræðilegar upplýsingar - chicken; ducks - fyrir virkan bólusetningu á hænur og öndum gegn fuglainflúensuveiru a, undirgerð h5. kjúklingar: minnkun á dánartíðni og útskilnaði vírusa eftir áskorun. upphaf ónæmis: 3 vikum eftir seinni inndælingu. lengd ónæmis í kjúklingum hefur ekki enn verið staðfest. endur: lækkun klínískum merki og veira skilst eftir áskorun. upphaf ónæmis: 3 vikum eftir seinni inndælingu. lengd ónæmis í öndum: 14 vikum eftir seinni inndælingu.
recuvyra
eli lilly and company limited - fentanýl - taugakerfi - hundar - til að stjórna verkjum í tengslum við hjálpartækjum og mjúkvefskurðaðgerð hjá hundum.
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svín - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
depomycine, vet. stungulyf, dreifa
intervet international b.v.* - benzylpenicillinprocainum; dihydrostreptomycinum súlfat - stungulyf, dreifa
carepen vet (caremast vet) spenalyf, dreifa 600 mg
vetcare oy - benzylpenicillinprocainum - spenalyf, dreifa - 600 mg